Title:
USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE
Document Type and Number:
WIPO Patent Application WO2004064753
Kind Code:
A3
Abstract:
Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.
Inventors:
WEINER DAVID M (US)
BRANN MARK R (US)
BRANN MARK R (US)
Application Number:
PCT/US2004/001509
Publication Date:
November 25, 2004
Filing Date:
January 21, 2004
Export Citation:
Assignee:
ACADIA PHARM INC (US)
WEINER DAVID M (US)
BRANN MARK R (US)
WEINER DAVID M (US)
BRANN MARK R (US)
International Classes:
A61K31/5513; A61P25/00; A61P25/18; A61P25/24; A61P25/28; A61P27/06; A61P29/00; (IPC1-7): A61K31/5513; A61P25/18; A61P25/00; A61P25/24; A61P25/28; A61P29/00; A61P27/06
Domestic Patent References:
| WO2002060870A2 | 2002-08-08 |
Foreign References:
| FR51F |
Other References:
SUR CYRILLE ET AL: "N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 23, 11 November 2003 (2003-11-11), pages 13674 - 13679, XP001191264, ISSN: 0027-8424
YOUNG CHERYL D ET AL: "Effects of desmethylclozapine on Fos protein expression in the forebrain: In vivo biological activity of the clozapine metabolite", NEUROPSYCHOPHARMACOLOGY, vol. 19, no. 1, July 1998 (1998-07-01), pages 99 - 103, XP001191184, ISSN: 0893-133X
OZDEMIR VURAL ET AL: "CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 21, no. 4, August 2001 (2001-08-01), pages 398 - 407, XP008031203, ISSN: 0271-0749
SPINA E ET AL: "Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. MAY 1998, vol. 13, no. 3, May 1998 (1998-05-01), pages 141 - 145, XP008031208, ISSN: 0268-1315
WEIGMANN H ET AL: "Does the pharmacologically active N-demethylated metabolite of clozapine pass the blood-brain barrier?", PHARMACOPSYCHIATRY, vol. 30, no. 5, September 1997 (1997-09-01), & 20TH SYMPOSIUM OF THE STUDY GROUP OF NEUROPSYCHOPHARMACOLOGY AND PHARMACOPSYCHIATRY (ARBEITSGEMEINSC; NUREMBERG, GERMANY; OCTOBER 8-11, 1997, pages 233, XP008031187, ISSN: 0176-3679
YOUNG CHERYL D ET AL: "Effects of desmethylclozapine on Fos protein expression in the forebrain: In vivo biological activity of the clozapine metabolite", NEUROPSYCHOPHARMACOLOGY, vol. 19, no. 1, July 1998 (1998-07-01), pages 99 - 103, XP001191184, ISSN: 0893-133X
OZDEMIR VURAL ET AL: "CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 21, no. 4, August 2001 (2001-08-01), pages 398 - 407, XP008031203, ISSN: 0271-0749
SPINA E ET AL: "Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. MAY 1998, vol. 13, no. 3, May 1998 (1998-05-01), pages 141 - 145, XP008031208, ISSN: 0268-1315
WEIGMANN H ET AL: "Does the pharmacologically active N-demethylated metabolite of clozapine pass the blood-brain barrier?", PHARMACOPSYCHIATRY, vol. 30, no. 5, September 1997 (1997-09-01), & 20TH SYMPOSIUM OF THE STUDY GROUP OF NEUROPSYCHOPHARMACOLOGY AND PHARMACOPSYCHIATRY (ARBEITSGEMEINSC; NUREMBERG, GERMANY; OCTOBER 8-11, 1997, pages 233, XP008031187, ISSN: 0176-3679
Download PDF:
Previous Patent: METHOD OF PREPARING SUSTAINED RELEASE MICROPARTICLES
Next Patent: BIOADHESIVE PHARMACEUTICAL COMPOSITIONS
Next Patent: BIOADHESIVE PHARMACEUTICAL COMPOSITIONS